XML 46 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Development and Other Agreements (Details) - Verily Life Sciences - Collaborative Arrangement - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2021
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2022
Mar. 31, 2022
Dec. 28, 2018
Nov. 30, 2018
Other Commitments [Line Items]                
Amortization period (in months)         64 months      
Initial Payment                
Other Commitments [Line Items]                
Closing stock price (in USD per share)             $ 29.57  
Initial payment on collaborative agreement   $ 250.0   $ 250.0        
Issuance of common stock in connection with acquisition, shares (in shares)   7,363,772            
Collaborative research and development fee $ 87.1     $ 217.7        
Milestone Payments                
Other Commitments [Line Items]                
Collaborative research and development fee     $ 3.2          
Potential future common stock issuable (in shares)               5,154,640
Sales-based milestones         $ 152.4      
Approval Milestone                
Other Commitments [Line Items]                
Potential future common stock issuable (in shares)           2,945,508